
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8377603/publications.pdf Version: 2024-02-01



KONCMING WU

#	Article	IF	CITATIONS
1	YB-1 is a positive regulator of KLF5 transcription factor in basal-like breast cancer. Cell Death and Differentiation, 2022, 29, 1283-1295.	11.2	23
2	Combination strategies with PD-1/PD-L1 blockade: current advances and future directions. Molecular Cancer, 2022, 21, 28.	19.2	393
3	Biological Characteristics and Clinical Significance of Soluble PD-1/PD-L1 and Exosomal PD-L1 in Cancer. Frontiers in Immunology, 2022, 13, 827921.	4.8	43
4	Notch signaling pathway: architecture, disease, and therapeutics. Signal Transduction and Targeted Therapy, 2022, 7, 95.	17.1	229
5	Targeting polarized phenotype of microglia via IL6/JAK2/STAT3 signaling to reduce NSCLC brain metastasis. Signal Transduction and Targeted Therapy, 2022, 7, 52.	17.1	43
6	Tumor organoids: applications in cancer modeling and potentials in precision medicine. Journal of Hematology and Oncology, 2022, 15, 58.	17.0	49
7	The role of exosomes in liquid biopsy for cancer diagnosis and prognosis prediction. International Journal of Cancer, 2021, 148, 2640-2651.	5.1	90
8	Immune signature-based risk stratification and prediction of immune checkpoint inhibitor's efficacy for lung adenocarcinoma. Cancer Immunology, Immunotherapy, 2021, 70, 1705-1719.	4.2	96
9	Prognostic significance of KRT19 in Lung Squamous Cancer. Journal of Cancer, 2021, 12, 1240-1248.	2.5	12
10	Regulation of PD-L1 expression in the tumor microenvironment. Journal of Hematology and Oncology, 2021, 14, 10.	17.0	281
11	The construction, expression, and enhanced anti-tumor activity of YM101: a bispecific antibody simultaneously targeting TGF-Î ² and PD-L1. Journal of Hematology and Oncology, 2021, 14, 27.	17.0	118
12	MiRNA-mediated EMT and CSCs in cancer chemoresistance. Experimental Hematology and Oncology, 2021, 10, 12.	5.0	47
13	Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC. Experimental Hematology and Oncology, 2021, 10, 18.	5.0	64
14	The biology of combination immunotherapy in recurrent metastatic head and neck cancer. International Journal of Biochemistry and Cell Biology, 2021, 136, 106002.	2.8	6
15	Rapid spread of a densovirus in a major crop pest following wide-scale adoption of Bt-cotton in China. ELife, 2021, 10, .	6.0	6
16	Epidemiological trends of women's cancers from 1990 to 2019 at the global, regional, and national levels: a population-based study. Biomarker Research, 2021, 9, 55.	6.8	67
17	Advances of Targeted Therapy for Hepatocellular Carcinoma. Frontiers in Oncology, 2021, 11, 719896.	2.8	23
18	A Modified Nucleoside 6-Thio-2′-Deoxyguanosine Exhibits Antitumor Activity in Gliomas. Clinical Cancer Research, 2021, 27, 6800-6814.	7.0	10

Консмінс Wu

#	Article	IF	CITATIONS
19	Combine and conquer: manganese synergizing anti-TGF-β/PD-L1 bispecific antibody YM101 to overcome immunotherapy resistance in non-inflamed cancers. Journal of Hematology and Oncology, 2021, 14, 146.	17.0	68
20	Synergistic resistance of Helicoverpa armigera to Bt toxins linked to cadherin and ABC transporters mutations. Insect Biochemistry and Molecular Biology, 2021, 137, 103635.	2.7	13
21	Roles of Microvesicles in Tumor Progression and Clinical Applications. International Journal of Nanomedicine, 2021, Volume 16, 7071-7090.	6.7	30
22	Roles of tumor-associated macrophages in tumor progression: implications on therapeutic strategies. Experimental Hematology and Oncology, 2021, 10, 60.	5.0	53
23	Recent advances and challenges of bispecific antibodies in solid tumors. Experimental Hematology and Oncology, 2021, 10, 56.	5.0	42
24	Distinct Roles of VEGFA and ANGPT2 in Lung Adenocarcinoma and Squamous Cell Carcinoma. Journal of Cancer, 2020, 11, 153-167.	2.5	24
25	Ferritins as natural and artificial nanozymes for theranostics. Theranostics, 2020, 10, 687-706.	10.0	80
26	The global, regional, and national burden of kidney cancer and attributable risk factor analysis from 1990 to 2017. Experimental Hematology and Oncology, 2020, 9, 27.	5.0	25
27	Cadherin repeat 5 mutation associated with Bt resistance in a field-derived strain of pink bollworm. Scientific Reports, 2020, 10, 16840.	3.3	8
28	Prognostic Values of TIM-3 Expression in Patients With Solid Tumors: A Meta-Analysis and Database Evaluation. Frontiers in Oncology, 2020, 10, 1288.	2.8	29
29	Upregulation of STAT1-CCL5 axis is a biomarker of colon cancer and promotes the proliferation of colon cancer cells. Annals of Translational Medicine, 2020, 8, 951-951.	1.7	11
30	CD38: targeted therapy in multiple myeloma and therapeutic potential for solid cancers. Expert Opinion on Investigational Drugs, 2020, 29, 1295-1308.	4.1	17
31	CD44 as a tumor biomarker and therapeutic target. Experimental Hematology and Oncology, 2020, 9, 36.	5.0	177
32	NRF2-Driven <i>KEAP1</i> Transcription in Human Lung Cancer. Molecular Cancer Research, 2020, 18, 1465-1476.	3.4	9
33	RDGN-based predictive model for the prognosis of breast cancer. Experimental Hematology and Oncology, 2020, 9, 13.	5.0	12
34	The global burden and attributable risk factor analysis of acute myeloid leukemia in 195 countries and territories from 1990 to 2017: estimates based on the global burden of disease study 2017. Journal of Hematology and Oncology, 2020, 13, 72.	17.0	123
35	Identifying Tumorigenesis and Prognosis-Related Genes of Lung Adenocarcinoma: Based on Weighted Gene Coexpression Network Analysis. BioMed Research International, 2020, 2020, 1-15.	1.9	26
36	The role of cancer-derived microRNAs in cancer immune escape. Journal of Hematology and Oncology, 2020, 13, 25.	17.0	145

#	Article	IF	CITATIONS
37	The roles of exosomes in cancer drug resistance and its therapeutic application. Clinical and Translational Medicine, 2020, 10, e257.	4.0	47
38	Global burden and trend of acute lymphoblastic leukemia from 1990 to 2017. Aging, 2020, 12, 22869-22891.	3.1	27
39	A novel asymmetrical anti-HER2/CD3 bispecific antibody exhibits potent cytotoxicity for HER2-positive tumor cells. Journal of Experimental and Clinical Cancer Research, 2019, 38, 355.	8.6	47
40	Next generation chimeric antigen receptor T cells: safety strategies to overcome toxicity. Molecular Cancer, 2019, 18, 125.	19.2	201
41	The efficacy and safety of combination of PD-1 and CTLA-4 inhibitors: a meta-analysis. Experimental Hematology and Oncology, 2019, 8, 26.	5.0	58
42	Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4. Molecular Cancer, 2019, 18, 155.	19.2	723
43	Manipulating Gut Microbiota Composition to Enhance the Therapeutic Effect of Cancer Immunotherapy. Integrative Cancer Therapies, 2019, 18, 153473541987635.	2.0	38
44	Prospects for combining immune checkpoint blockade with PARP inhibition. Journal of Hematology and Oncology, 2019, 12, 98.	17.0	92
45	EYA2 Correlates With Clinico-Pathological Features of Breast Cancer, Promotes Tumor Proliferation, and Predicts Poor Survival. Frontiers in Oncology, 2019, 9, 26.	2.8	17
46	Dachshund Depletion Disrupts Mammary Gland Development and Diverts the Composition of the Mammary Gland Progenitor Pool. Stem Cell Reports, 2019, 12, 135-151.	4.8	10
47	Transposon insertion causes cadherin mis-splicing and confers resistance to Bt cotton in pink bollworm from China. Scientific Reports, 2019, 9, 7479.	3.3	31
48	<scp>SALL</scp> 4 induces radioresistance in nasopharyngeal carcinoma via the <scp>ATM</scp> /Chk2/p53 pathway. Cancer Medicine, 2019, 8, 1779-1792.	2.8	38
49	Recent advances on anti-angiogenesis receptor tyrosine kinase inhibitors in cancer therapy. Journal of Hematology and Oncology, 2019, 12, 27.	17.0	211
50	Recent progress on the interaction between insects and <i>Bacillus thuringiensis</i> crops. Philosophical Transactions of the Royal Society B: Biological Sciences, 2019, 374, 20180316.	4.0	94
51	Synergistic effect of immune checkpoint blockade and anti-angiogenesis in cancer treatment. Molecular Cancer, 2019, 18, 60.	19.2	361
52	Pink Bollworm Resistance to Bt Toxin Cry1Ac Associated with an Insertion in Cadherin Exon 20. Toxins, 2019, 11, 186.	3.4	29
53	Activating cCAS-STING pathway for the optimal effect of cancer immunotherapy. Journal of Hematology and Oncology, 2019, 12, 35.	17.0	220
54	Advances and perspectives of PARP inhibitors. Experimental Hematology and Oncology, 2019, 8, 29.	5.0	81

Консмінс Wu

#	Article	IF	CITATIONS
55	SIX1 Activates STAT3 Signaling to Promote the Proliferation of Thyroid Carcinoma via EYA1. Frontiers in Oncology, 2019, 9, 1450.	2.8	29
56	<p>Blocking TGF-β Signaling To Enhance The Efficacy Of Immune Checkpoint Inhibitor</p> . OncoTargets and Therapy, 2019, Volume 12, 9527-9538.	2.0	93
57	Immune pressures drive the promoter hypermethylation of neoantigen genes. Experimental Hematology and Oncology, 2019, 8, 32.	5.0	11
58	CXCL1 as an Unfavorable Prognosis Factor Negatively Regulated by DACH1 in Non-small Cell Lung Cancer. Frontiers in Oncology, 2019, 9, 1515.	2.8	29
59	Resistance to Bacillus thuringiensis linked with a cadherin transmembrane mutation affecting cellular trafficking in pink bollworm from China. Insect Biochemistry and Molecular Biology, 2018, 94, 28-35.	2.7	37
60	Dachshund 1 is Differentially Expressed Between Male and Female Breast Cancer: A Matched Case-Control Study of Clinical Characteristics and Prognosis. Clinical Breast Cancer, 2018, 18, e875-e882.	2.4	4
61	Gut microbiome modulates efficacy of immune checkpoint inhibitors. Journal of Hematology and Oncology, 2018, 11, 47.	17.0	138
62	DACH1 antagonizes CXCL8 to repress tumorigenesis of lung adenocarcinoma and improve prognosis. Journal of Hematology and Oncology, 2018, 11, 53.	17.0	72
63	Developing TRAIL/TRAIL death receptor-based cancer therapies. Cancer and Metastasis Reviews, 2018, 37, 733-748.	5.9	158
64	The role of gut microbiota in immune checkpoint inhibitor therapy. Hepatobiliary Surgery and Nutrition, 2018, 7, 481-483.	1.5	16
65	The role of neoantigen in immune checkpoint blockade therapy. Experimental Hematology and Oncology, 2018, 7, 28.	5.0	99
66	Organoid technology in disease modelling, drug development, personalized treatment and regeneration medicine. Experimental Hematology and Oncology, 2018, 7, 30.	5.0	119
67	The regulation of cytokine signaling by retinal determination gene network pathway in cancer. OncoTargets and Therapy, 2018, Volume 11, 6479-6487.	2.0	17
68	Progression and prognostic value of ECT2 in non-small-cell lung cancer and its correlation with PCNA. Cancer Management and Research, 2018, Volume 10, 4039-4050.	1.9	12
69	Organoid technology and applications in cancer research. Journal of Hematology and Oncology, 2018, 11, 116.	17.0	196
70	MAT1 correlates with molecular subtypes and predicts poor survival in breast cancer. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2018, 30, 351-363.	2.2	5
71	Retinoic acid-induced 2 (RAI2) is a novel tumor suppressor, and promoter region methylation of RAI2 is a poor prognostic marker in colorectal cancer. Clinical Epigenetics, 2018, 10, 69.	4.1	21
72	EGFR-TKIs resistance via EGFR-independent signaling pathways. Molecular Cancer, 2018, 17, 53.	19.2	223

#	Article	IF	CITATIONS
73	Biomarkers for predicting efficacy of PD-1/PD-L1 inhibitors. Molecular Cancer, 2018, 17, 129.	19.2	536
74	A Single Point Mutation Resulting in Cadherin Mislocalization Underpins Resistance against Bacillus thuringiensis Toxin in Cotton Bollworm. Journal of Biological Chemistry, 2017, 292, 2933-2943.	3.4	39
75	Recent advances of highly selective CDK4/6 inhibitors in breast cancer. Journal of Hematology and Oncology, 2017, 10, 97.	17.0	126
76	Chimeric antigen receptor T cells: a novel therapy for solid tumors. Journal of Hematology and Oncology, 2017, 10, 78.	17.0	232
77	Targeting interlukin-6 to relieve immunosuppression in tumor microenvironment. Tumor Biology, 2017, 39, 101042831771244.	1.8	55
78	Prostate-specific IL-6 transgene autonomously induce prostate neoplasm through amplifying inflammation in the prostate and peri-prostatic adipose tissue. Journal of Hematology and Oncology, 2017, 10, 14.	17.0	19
79	DACH1 suppresses breast cancer as a negative regulator of CD44. Scientific Reports, 2017, 7, 4361.	3.3	32
80	OK-432 (Sapylin) Reduces Seroma Formation After Axillary Lymphadenectomy in Breast Cancer. Journal of Investigative Surgery, 2017, 30, 1-5.	1.3	14
81	The clinical significance of CXCL5 in non-small cell lung cancer. OncoTargets and Therapy, 2017, Volume 10, 5561-5573.	2.0	36
82	Recent advances of bispecific antibodies in solid tumors. Journal of Hematology and Oncology, 2017, 10, 155.	17.0	121
83	Development and clinical application of anti-HER2 monoclonal and bispecific antibodies for cancer treatment. Experimental Hematology and Oncology, 2017, 6, 31.	5.0	64
84	ONC201 activates ER stress to inhibit the growth of triple-negative breast cancer cells. Oncotarget, 2017, 8, 21626-21638.	1.8	30
85	Meta-analysis comparing the efficacy of nedaplatin-based regimens between squamous cell and non-squamous cell lung cancers. Oncotarget, 2017, 8, 62330-62338.	1.8	5
86	Stromal cyclin D1 promotes heterotypic immune signaling and breast cancer growth. Oncotarget, 2017, 8, 81754-81775.	1.8	32
87	Enrichment of CD44 in basal-type breast cancer correlates with EMT, cancer stem cell gene profile, and prognosis. OncoTargets and Therapy, 2016, 9, 431.	2.0	50
88	A novel paclitaxel-loaded poly(D,L-lactide-co-glycolide)-Tween 80 copolymer nanoparticle overcoming multidrug resistance for lung cancer treatment. International Journal of Nanomedicine, 2016, 11, 2119.	6.7	17
89	Resistance to Bacillus thuringiensis Mediated by an ABC Transporter Mutation Increases Susceptibility to Toxins from Other Bacteria in an Invasive Insect. PLoS Pathogens, 2016, 12, e1005450.	4.7	45
90	Modification of platinum sensitivity by KEAP1/NRF2 signals in non-small cell lung cancer. Journal of Hematology and Oncology, 2016, 9, 83.	17.0	45

#	Article	IF	CITATIONS
91	CD44 correlates with clinicopathological characteristics and is upregulated by EGFR in breast cancer. International Journal of Oncology, 2016, 49, 1343-1350.	3.3	52
92	Left lower limb may be a forbidden region for indwelling needle during operation. Thrombosis Research, 2016, 144, 165-168.	1.7	0
93	The CXCL8-CXCR1/2 pathways in cancer. Cytokine and Growth Factor Reviews, 2016, 31, 61-71.	7.2	471
94	The expression profile and clinic significance of the SIX family in non-small cell lung cancer. Journal of Hematology and Oncology, 2016, 9, 119.	17.0	57
95	Emerging roles of Nrf2 signal in non-small cell lung cancer. Journal of Hematology and Oncology, 2016, 9, 14.	17.0	50
96	The <scp>DACH/EYA/SIX</scp> gene network and its role in tumor initiation and progression. International Journal of Cancer, 2016, 138, 1067-1075.	5.1	68
97	GRIM-19 inhibition induced autophagy through activation of ERK and HIF-1α not STAT3 in Hela cells. Tumor Biology, 2016, 37, 9789-9796.	1.8	17
98	The retinal determination gene network: from developmental regulator to cancer therapeutic target. Oncotarget, 2016, 7, 50755-50765.	1.8	34
99	The inhibitory effects of AR/miR-190a/YB-1 negative feedback loop on prostate cancer and underlying mechanism. Scientific Reports, 2015, 5, 13528.	3.3	24
100	The role of CD44 in epithelial–mesenchymal transition and cancer development. OncoTargets and Therapy, 2015, 8, 3783.	2.0	154
101	Meta-analysis reveals the correlation of Notch signaling with non-small cell lung cancer progression and prognosis. Scientific Reports, 2015, 5, 10338.	3.3	96
102	The Endogenous Cell-Fate Factor Dachshund Restrains Prostate Epithelial Cell Migration via Repression of Cytokine Secretion via a CXCL Signaling Module. Cancer Research, 2015, 75, 1992-2004.	0.9	34
103	Quantitative Analysis of Fitness Costs Associated with the Development of Resistance to the Bt Toxin Cry1Ac in Helicoverpa armigera. Scientific Reports, 2015, 4, 5629.	3.3	34
104	Non-invasive approaches to monitor EGFR-TKI treatment in non-small-cell lung cancer. Journal of Hematology and Oncology, 2015, 8, 95.	17.0	81
105	Notch signaling: An emerging therapeutic target for cancer treatment. Cancer Letters, 2015, 369, 20-27.	7.2	336
106	Large-scale test of the natural refuge strategy for delaying insect resistance to transgenic Bt crops. Nature Biotechnology, 2015, 33, 169-174.	17.5	167
107	A Toxin-Binding Alkaline Phosphatase Fragment Synergizes Bt Toxin Cry1Ac against Susceptible and Resistant Helicoverpa armigera. PLoS ONE, 2015, 10, e0126288.	2.5	39
108	Expression of Notch1 Correlates with Breast Cancer Progression and Prognosis. PLoS ONE, 2015, 10, e0131689.	2.5	75

#	Article	IF	CITATIONS
109	Endogenous Dach1 in cancer. Oncoscience, 2015, 2, 803-804.	2.2	7
110	DACH1 is a novel predictive and prognostic biomarker in hepatocellular carcinoma as a negative regulator of Wnt/l²-catenin signaling. Oncotarget, 2015, 6, 8621-8634.	1.8	42
111	DACH1 inhibits lung adenocarcinoma invasion and tumor growth by repressing CXCL5 signaling. Oncotarget, 2015, 6, 5877-5888.	1.8	40
112	Interplay of retinal determination gene network with TGF-β signaling pathway in epithelial-mesenchymal transition. Stem Cell Investigation, 2015, 2, 12.	3.0	6
113	Silencing DACH1 Promotes Esophageal Cancer Growth by Inhibiting TGF-Î ² Signaling. PLoS ONE, 2014, 9, e95509.	2.5	26
114	DACH1 inhibits cyclin D1 expression, cellular proliferation and tumor growth of renal cancer cells. Journal of Hematology and Oncology, 2014, 7, 73.	17.0	54
115	Epigenetic silencing of <i><scp>DACH</scp>1</i> induces the invasion and metastasis of gastric cancer by activating <scp>TGF</scp> â€i² signalling. Journal of Cellular and Molecular Medicine, 2014, 18, 2499-2511.	3.6	34
116	Notch signaling and EMT in non-small cell lung cancer: biological significance and therapeutic application. Journal of Hematology and Oncology, 2014, 7, 87.	17.0	196
117	Cell Fate Factor DACH1 Represses YB-1–Mediated Oncogenic Transcription and Translation. Cancer Research, 2014, 74, 829-839.	0.9	68
118	Mis-splicing of the ABCC2 gene linked with Bt toxin resistance in Helicoverpa armigera. Scientific Reports, 2014, 4, 6184.	3.3	136
119	CAMK2N1 inhibits prostate cancer progression through androgen receptor-dependent signaling. Oncotarget, 2014, 5, 10293-10306.	1.8	52
120	Dachshund Binds p53 to Block the Growth of Lung Adenocarcinoma Cells. Cancer Research, 2013, 73, 3262-3274.	0.9	55
121	EYA1 Phosphatase Function Is Essential to Drive Breast Cancer Cell Proliferation through Cyclin D1. Cancer Research, 2013, 73, 4488-4499.	0.9	80
122	Epigenetic silencing of DACH1 induces loss of transforming growth factor- <i>β</i> 1 antiproliferative response in human hepatocellular carcinoma. Hepatology, 2013, 58, 2012-2022.	7.3	56
123	Epigenetic regulation of <i>DACH1</i> , a novel Wnt signaling component in colorectal cancer. Epigenetics, 2013, 8, 1373-1383.	2.7	79
124	Acetylation of the Cell-Fate Factor Dachshund Determines p53 Binding and Signaling Modules in Breast Cancer. Oncotarget, 2013, 4, 923-935.	1.8	27
125	Diverse genetic basis of field-evolved resistance to Bt cotton in cotton bollworm from China. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 10275-10280.	7.1	158
126	Reduced Levels of Membrane-Bound Alkaline Phosphatase Are Common to Lepidopteran Strains Resistant to Cry Toxins from Bacillus thuringiensis. PLoS ONE, 2011, 6, e17606.	2.5	139

#	Article	IF	CITATIONS
127	Cell Fate Determination Factor Dachshund Reprograms Breast Cancer Stem Cell Function. Journal of Biological Chemistry, 2011, 286, 2132-2142.	3.4	74
128	Attenuation of Forkhead signaling by the retinal determination factor DACH1. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 6864-6869.	7.1	58
129	The Dachshund gene in development and hormone-responsive tumorigenesis. Trends in Endocrinology and Metabolism, 2010, 21, 41-49.	7.1	65
130	The Cell Fate Determination Factor DACH1 Is Expressed in Estrogen Receptor-α–Positive Breast Cancer and Represses Estrogen Receptor-α Signaling. Cancer Research, 2009, 69, 5752-5760.	0.9	61
131	The Cell Fate Determination Factor Dachshund Inhibits Androgen Receptor Signaling and Prostate Cancer Cellular Growth. Cancer Research, 2009, 69, 3347-3355.	0.9	74
132	Reduction of Bacillus thuringiensis Cry1Ac toxicity against Helicoverpa armigera by a soluble toxin-binding cadherin fragment. Journal of Insect Physiology, 2009, 55, 686-693.	2.0	25
133	Mutation of an aminopeptidase N gene is associated with Helicoverpa armigera resistance to Bacillus thuringiensis Cry1Ac toxin. Insect Biochemistry and Molecular Biology, 2009, 39, 421-429.	2.7	146
134	Dachshund inhibits oncogene-induced breast cancer cellular migration and invasion through suppression of interleukin-8. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 6924-6929.	7.1	92
135	Cell Fate Determination Factor DACH1 Inhibits c-Jun–induced Contact-independent Growth. Molecular Biology of the Cell, 2007, 18, 755-767.	2.1	68
136	DACH1 Is a Cell Fate Determination Factor That Inhibits Cyclin D1 and Breast Tumor Growth. Molecular and Cellular Biology, 2006, 26, 7116-7129.	2.3	121
137	DACH1 Inhibits Transforming Growth Factor-β Signaling through Binding Smad4. Journal of Biological Chemistry, 2003, 278, 51673-51684.	3.4	125